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Background. CD8+ T cells impact control of viral infections by direct elimination of infected cells and secretion of a number of
soluble factors. In HIV-1 infection, persistent HIV-1 specific IFN-c+ CD8+ T cell responses are detected in the setting of disease
progression, consistent with functional impairment in vivo. Recent data suggest that impaired maturation, as defined by the
lineage markers CD45RA and CCR7, may contribute to a lack of immune control by these responses. Methodology/Principal
Findings. We investigated the maturation phenotype of epitope-specific CD8+ T cell responses directed against HIV-1 in 42
chronically infected, untreated individuals, 22 of whom were ‘‘Controllers’’ (median 1140 RNA copies/ml plasma, range,50 to
2520), and 20 ‘‘progressors’’ of whom had advanced disease and high viral loads (median 135,500 RNA copies/ml plasma, range
12100 to .750000). Evaluation of a mean of 5 epitopes per person revealed that terminally differentiated CD8+ T cells directed
against HIV-1 are more often seen in HIV-1 Controllers (16/22; 73%) compared to HIV-1 progressors (7/20; 35%)(p=0.015), but
the maturation state of epitope-specific responses within a given individual was quite variable. Maturation phenotype was
independent of the HLA restriction or the specificity of a given CD8+ T cell response and individual epitopes associated with
slow disease progression were not more likely to be terminally differentiated. Conclusions/Significance. These data indicate
that although full maturation of epitope-specific CD8+ T cell responses is associated with viral control, the maturation status of
HIV-1 specific CD8+ T cell responses within a given individual are quite heterogeneous, suggesting epitope-specific influences
on CD8+ T cell function.
Citation: Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, et al (2007) Fully Differentiated HIV-1 Specific CD8+ T Effector Cells Are More Frequently
Detectable in Controlled than in Progressive HIV-1 Infection. PLoS ONE 2(3): e321. doi:10.1371/journal.pone.0000321
INTRODUCTION
An increasing body of evidence suggests that HIV-1 specific T cells
contribute to viral control in HIV-1 infection. CD8+ T cell
responses in particular are thought to be crucial for control of
HIV-1 viremia by direct elimination of infected cells and secretion
of a number of soluble factors, but ultimately fail to control
viremia in most infected persons (reviewed in[1–3]). HIV-1
specific CD8+ T cells appear coincident with the initial drop in
HIV-1 viral loads during primary HIV-infection, which suggests
a role for these cells in containment of viral replication [4,5].
Further evidence for the antiviral activity of + T cells is provided
by the simian AIDS model, in which animals fail to contain initial
viremia upon depletion of CD8+ cells at the time of infection [6,7].
Moreover, growing evidence of viral escape within CD8+ T cell
epitopes during acute and chronic SIV or HIV-1 infection
demonstrate that CD8+ T cells can exert strong immune selection
pressure on the virus [8–10,11,12,13], although the evidence for
ongoing selection pressure in chronic infection is less clear-cut
[14].
Despite this strong evidence of an antiviral effect of CD8+ T
cells, most infected persons experience progressive loss of CD4+ T
cells and increase in plasma viremia and ultimately develop clinical
AIDS. Recent data suggest that the breadth and magnitude of the
CD8+ T cell response directed against HIV-1 as measured by
IFN-c production does not correlate with HIV-1 viral load [15–
17]. Furthermore HIV-1 specific CD8+ T cells persist in high
numbers in persons with untreated chronic progressive disease and
no quantitative differences in the HIV-1 specific T cell response
were observed between individuals with progressive and long-term
non-progressive infection [14–16]. These findings suggest that
CD8+ T cell characteristics that determine differences in HIV-1
disease outcomes may be of a qualitative rather than a quantitative
nature.
Studies have demonstrated that HIV-1 specific CD8+ T cells
are impaired in their cytolytic function in chronic progressive
infection [18,19], and it was suggested that the inability of virus-
specific CD8+ T cells to control viremia in chronic HIV-1
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PLoS ONE | www.plosone.org 1 March 2007 | Issue 3 | e321infection may be linked to failure of these lymphocytes to fully
mature into effector cell [20]. In particular, a block in the
maturation of virus-specific CD8+ T cells from an effector
memory phenotype to terminally differentiated effector cell has
been proposed in chronic progressive HIV-1 infection [20]. We
therefore hypothesized that individuals with exquisite long-term
control of viral replication during untreated chronic HIV-1
infection would possess significantly higher numbers of terminally
differentiated CD8+ T cells directed against HIV-1 compared to
subjects with progressive disease.
To address this hypothesis we determined the HIV-1 specific
CD8+ T cell response to the entire expressed HIV-1 proteome and
investigated the differentiation phenotype of 253 HIV-1 specific T
cell responses using the lineage markers CD45RA and CCR7 in
two very distinct HIV-1 infected study populations: a cohort of 22
individuals who were able to maintain control of viremia (median
1140 RNA copies/ml, range,50–2520) without the need for
antiretroviral therapy (HIV-1 Controllers), and 20 HIV-1 infected
individuals with untreated progressive chronic HIV-1 infection
and high plasma viral loads (HIV-1 progressors). Our results
demonstrate that HIV-1-specific CD8+ T cells of mature effector
phenotype are more frequently detectable in HIV-1 Controllers
than in HIV-1 progressors, but that the maturation status of HIV-
1 specific CD8+ T cell responses within a given individual is quite
heterogeneous, suggesting epitope-specific influences on matura-
tion status.
METHODS
Study subjects
Forty-two individuals with chronic untreated HIV-1 infection
were recruited from the Massachusetts General Hospital (MGH),
the Lemuel Shattuck Hospital and the Fenway Community Health
Center in Boston, USA. Twenty-two study subjects were
asymptomatic treatment-naı ¨ve individuals with persistent long-
term control (median 15 years, range 3–22) of HIV-1 viremia
,3000 RNA copies/ml (Roche Amplicor Assay Version 1.0) in
the absence of any antiretroviral therapy (‘‘HIV-1 Controllers’’).
The median plasma viral load in these HIV-1 controllers was 1140
HIV-1 RNA copies/ml (range,50 to 2520) and the median CD4
T cell count was 664 cells/ml (range 440–1097). Twenty additional
study subjects had chronic progressive HIV-1 infection and
fulfilled at least one of three criteria: HIV-1 plasma viral
load.45,000 copies/ml, CD4 count,350/ml or an AIDS defining
illness (‘‘HIV-1 Progressors’’)[14]. Among the HIV-1 Progressors
the plasma viral load ranged from 12,100 to .750,000 (median
135,500) HIV-1 RNA copies/ml and the median CD4 T cell
count was 245 cells/ml (range 12–630). Both, viral loads and
CD4+ T cell counts differed significantly between the two cohorts
(p=0.0005 and p,0.0001, respectively). Clinical and demograph-
ic characteristics of the study subjects are summarized in table 1.
The study was approved by the Institutional Review Boards of the
participating institutions and all individuals gave informed consent
for participation in the studies.
Peptides
Peptides were synthesized using an automated peptide synthesizer
(MBS 396; Advanced Chemtech, Louisville, USA) using fluor-
enylmethoxycarbonyl chemistry. Four-hundred and ten peptides
(16 to 19 amino acids long, 10 amino acid overlap, consensus
sequence clade B 2001 (http://hiv-web.lanl.gov)) spanning all
expressed HIV-1 proteins (Gag, Nef, Rev, Tat, Vpu, Vpr, Pol,
Env, Vif) were synthesized as well as 8 to 11mer peptides corre-
sponding to HLA-matched optimal epitopes previously described
in the literature [21]. Clade B consensus sequence was chosen as
the large majority of individuals in Boston are infected with HIV-1
clade B.
Elispot assay
HIV-1 specific CD8+ T cell responses were quantified by Elispot
assay using fresh peripheral blood mononuclear cells (PBMC)
(0.5–1610
5 per well) and single peptides (final concentration:
14 mg/ml), as described previously [14,15]. Briefly, fresh PBMC
were plated in 96-well polyvinylidene plates (Millipore, Bedford,
Mass.) that had been precoated with 0.5 mg of anti-IFN-c
monoclonal antibody, 1-DIK (Mabtech, Stockholm, Sweden)/
ml. PBMC were added at a concentration of 100,000 cells per well
in a volume of 100 ml of R10 medium (RPMI 1640,Sigma; 10%
fetal calf serum; Sigma, 10 mM HEPES buffer; Sigma) with
antibiotics (2 mM L-glutamine, 50 U of penicillin-streptomycin/
ml). The final concentration of the peptides in the well was 20 mg/
ml. Plates were incubated overnight at 37uC, 5% CO2, and
developed as described previously [22]. Wells containing PBMC
and R10 medium were used as negative controls and were run in
triplicate on each plate. IFN-c-producing cells were counted by
direct visualization on an automatic Elispotreader (AID Immun-
diagnostika, Germany) and are expressed as spot-forming cells
(SFC) per 10
6 PBMC. Negative controls were always ,/=30 SFC
per 10
6 input cells. Positive controls consisted of incubation of
PBMC with phytohemagglutinin (PHA), and only assays with
PBMC in which PHA induced a significant stimulation, as defined
by an well that was entirely covered with spots (‘‘black well’’) were
included in the analysis to eliminate false negative results from
damaged PBMC. Wells were counted as positive if they were at
least 60 SFC/10
6 PBMC and at least three times above back-
ground [15]. Breadth and magnitude were determined as
described previously [15].
Flow-cytometric detection of antigen-induced
intracellular cytokine secretion and maturation
phenotype
Based on the full-proteome Elispot screening a median of 5 (range
3–12) immunodominant peptides per patient (defined as the
strongest HIV-1-specific CD8+ T cell responses in a given
individual) were selected for further flow-cytometry-based analysis.
In a subset of experiments pools of overlapping peptides spanning
the HIV-1 proteins Gag, Pol, Env and Nef were used as antigens.
Intracellular staining assays were carried out as described pre-
viously [23,24]. Briefly, frozen PBMC were incubated with 20 ml
of peptide with PBMC and 1 mg/ml of anti-CD28 and anti-
Table 1. Clinical characteristics of study cohorts*.
......................................................................
Parameter Controllers n=22 Progressors n=20
Viral load (copies/ml) 1140 (,50–2520) 135,500 (12,900–
.750,000)
CD4 count (cells/ml) 664 (440–1722) 254 (12–630)
Age 42 (26–64) 45 (33–73)
Gender (M/F) 18/5 13/7
Race (cauc./non-cauc.) 16/7 15/5
M=male; F=female;
*Clinical and immunologic data for some of the HIV-1 progressors have
previously been described [14,15].
All study subjects were without antiretroviral treatment.
doi:10.1371/journal.pone.0000321.t001
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PLoS ONE | www.plosone.org 2 March 2007 | Issue 3 | e321CD49d antibodies (BD Biosciences) were added. Cells were
incubated for one hour at 37uC, 5% CO2, followed by an
additional 5 hours in the presence of a secretion inhibitor
(Brefeldin A, 10mg/ml, Sigma). Cells were then stained with
surface antibodies (CD8, CCR7, CD45RA; BD Biosciences) at
4uC for 30 minutes. After two washes, cells were fixed and per-
meabilized using the Caltag Cell Fixation and Permeabilization kit
according to the manufacturer’s protocol (Caltag, Burlingame,
CA). Subsequently, intracellular antigen staining was performed
using 15 ml of anti-IFN-c specific monoclonal antibodies (BD
Biosciences). Cells were then washed and analyzed on a FACS
Calibur flowcytometry instrument (BD Biosciences) using FITC,
PE, PerCP and APC as fluorescent parameters. Control conditions
were established by the use of autologous PBMC, which had not
been stimulated with peptide, but otherwise had been treated
identically. PBMC stimulated with Phorbol-12-myristat-13-acetat/
Ionomycin (PMA/I) were used as positive controls, and only assays
in which .10% of cells in the lymphocyte gate responded to
PMA/I stimulation were included in the analysis to control for
false negative results from damaged PBMC. An IFN-c- response
was considered positive if .0.03% and $3x the background IFN-
c production. An HIV-1 specific CD8+ T cell response with
.20% of CD45RA+/CCR7- cells was considered to be of
terminally differentiated effector phenotype in this study, as
described previously [25].
Statistical analysis
Data are indicated as median and range or means and standard
deviations. Differences between nominal data were tested for
statistical significance by use of the paired Wilcoxon rank sum test
or Mann Whitney two-tailed t-test. A p-value of ,0.05 was
considered significant. Differences between categorical data were
calculated using Fisher’s exact test. Data analysis and graphical
presentation were performed using the Graphpad Prism 4.0
software package.
RESULTS
HIV-1 specific T cell responses do not differ in
breadth and magnitude between HIV-1 Controllers
and HIV-1 Progressors
In order to determine the exact epitopic regions targeted by HIV-
1-specific CD8+ T cells in infected individuals, we first performed
a full proteome screening for HIV-1 specific T cell responses by
IFN-c Elispot using 410 overlapping peptides spanning HIV-1
clade B in all study subjects. The median magnitude of the total
HIV-1-specific response in HIV-1 Controllers was 9,110 SFC/10
6
PBMC (range 1,259 to 50,100) compared to 5,756.5 SFC/10
6
PBMC (range 710 to 21,380) in HIV-1 Progressors. HIV-1
Controllers recognized a median of 18 epitopic regions (range 4-
51) compared to 15 in the Progressor cohort (range 1 to 39). In line
with results in chronic HIV-1 infection [16,17,26], no statistical
difference was observed between either breadth or magnitude of
the HIV-1-specific T cell response as measured by IFN-c-
production in HIV-1 Controllers and Progressors (p=0.5 and
p=0.21, respectively), as previously reported for a small subset of
these study subjects [14,15].
Fully differentiated CD8+ T cells were more
frequently detected in HIV-1 Controllers
Recent data suggest a model of differentiation from naı ¨ve to
antigen-specific memory T cells based on the lineage markers
CCR7, which is a lymph node homing receptor and the RA
isoform of CD45, which is a marker expressed on naı ¨ve
lymphocytes, and is re-expressed at the fully mature stage of
differentiation. Using these two parameters, a differentiation block
from effector memory cells (CCR7
2/CCD45RA
2) to terminally
differentiated effector cells (CCR7
2/CD45RA
+) has been re-
ported in chronic progressive HIV-1 infection, resulting in
a relative paucity of fully mature virus-specific effector CD8+ T
cells [20,27]. Based on this model and the lack of quantitative
differences in the HIV-1 specific cellular immune response
measured by IFN-c secretion described above [14,26], we
hypothesized that HIV-1 Controllers would posses significantly
higher numbers of terminally differentiated CD8+ T cells in
directly isolated PBMC compared to HIV-1 Progressors.
To investigate this hypothesis, we examined maturation
phenotype in unstimulated bulk CD8+ T cells from persons with
progressive and controlled infection. Based on the expression of
the markers CD45RA and CCR7, HIV-1 Controllers had
a significantly higher frequency of fully differentiated effector
CD8+ cells (CD45RA+/CCR72) compared to HIV-1 Progressors
(p=0.02). In contrast, HIV-1 Progressors had higher mean
frequencies of effector memory (CD45RA
2/CCR7
2), central
memory (CD45RA
2/CCR7
+) and naı ¨ve T cells (CD45RA
+/
CCR7
+) compared to HIV-1 Controllers, but these differences
reached statistical significance only for the central memory cell
subset (p=0.03)(Figure 1a), and the lower proportion of central
memory bulk CD8+ T cell subsets in the Controllers might be
a reflection of the relative increase in the fraction of fully
differentiated effector cells.
Given these results with unstimulated bulk CD8+ T cells, we
next investigated the maturation phenotype of the HIV-1-specific
fraction of CD8+ T cells. Four pools of overlapping peptides
corresponding to the individual HIV-1 proteins Gag, Pol, Env and
Nef, respectively, were used as antigenic stimuli for IFN-c ICS
assays in 10 randomly-selected individuals: five HIV-1 Controllers
and 5 HIV-1 progressors. The use of peptide pools as antigenic
stimulation did not allow us to detect differences in the differ-
entiation status of HIV-1-specific CD8+ T cells between Control-
lers and Progressors (p=0.44 Fisher’s exact, data not shown).
HIV-1-specific CD8+ T cell responses to different
epitopes within the same HIV-1 protein differ in
their differentiation status
The above-described approach using pools of overlapping peptides
spanning individual HIV-1 proteins to stimulate HIV-1-specific
CD8+ T cell responses did not allow one to differentiate among
Figure 1. T cell differentiation profile in bulk CD8+ T cells. Based on
the lineage markers, CD45RA and CCR7 bulk CD8+ T cells of HIV-1
Controllers (black bars) and HIV-1 progressors (hatched bars) were
stratified into 4 subpopulations: effector (E), effector memory (EM),
central memory (CM) and naı ¨ve (N) CD8+ T cells. Terminally differ-
entiated (E) CD8+ T cells were of significantly higher frequency in HIV-1
Controllers (p=0.017, Mann-Whitney), while Progressors had higher
levels of CM cells (p=0.02), indicated by asterisks (*).
doi:10.1371/journal.pone.0000321.g001
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pool, as the potential presence of phenotypic heterogeneity would
obscure detection of differences. We therefore compared results
using the 4 peptide pools to results obtained using individual
overlapping peptides corresponding to specific immunodominant
CD8+ T cell responses within the same protein in a subset of eight
individuals (4 Controllers, 4 Progressors). In 5/8 (62%) individuals,
a single fully mature response to an HIV-1 specific epitope was not
reflected in the peptide pool corresponding to the protein, which
as a whole showed ,20% CD45RA+/CCR72 protein-specific
CD8+ T cells. Figure 2 shows that for a representative study
subject, within a single individual, the CD8+ T cell response to the
same protein antigen, in this case Pol, can include both terminally
differentiated CD8+ T cell responses to one epitope (Pol 356–374,
figure 2 C and D) and non-terminally differentiated CD8+ T cell
responses to one or more other epitopes, as reflected by the entire
Pol peptide pool (Fig 2A and B). Overall, the single mature CD8+
T cell response to peptide Pol 356–374 (32% CD45RA+CCR72
CD8+ T cells) was diluted in the cells stimulated by the entire Pol
pool, which as a whole does not reflect a fully mature phenotype
(8.8% CD45RA+CCR72 CD8+ T cells). Given these data
demonstrating that the use of peptide pools may obscure
differences in maturation phenotype on the single epitope level,
we extended the examination of the maturation status of indivi-
dual epitope-specific CD8+ T cell responses to the total study
population of 44 subjects.
Detailed maturation phenotype analysis on the
single epitope level reveals higher frequencies of
terminally differentiated CD8+ T cells in HIV-1
Controllers
We chose the detailed single epitope analysis outlined above to
evaluate a total of 126 immunodominant HIV-1 specific CD8+ T
cell responses in the HIV-1 Controllers (median: 5, range 3–12 per
individual) and 106 responses in the HIV-1 progressors (median:
5, range 1–12) for expression of CCR7 and CD45RA (note that
for the one individual with only one investigated CD8+ response,
this response represented the only detectable HIV-1 specific T cell
response, in all other subjects at least 3 responses were analyzed).
By using peptides that were previously shown to be recognized by
CD8+ T cell responses in the respective study subjects, we were
able to test both immunodominant T cell epitopes that had not
been optimally defined as well as epitopes restricted by HLA alleles
for which tetramers were not readily available.
As depicted in figure 3a, flow-cytometry-based investigation of
all CD8+ T cell responses tested for maturation phenotype in the
two study populations revealed that the median percentage of
terminally differentiated CD45RA
+/CCR7
2HIV-1specificCD8+
T cell responses was significantly different between HIV-1
Controllers and HIV-1 Progressors (p=0.013). In addition, 16/
22 (73%) of HIV-1 Controllers had at least one terminally
Figure 2. The effector phenotype of an individual CD8+T cell response may not be adequately reflected in a peptide pool. Panels A and C show
IFN-c production upon stimulation with the Pol peptide pool (A) and an individual Pol peptide (C). Panels B and D are gated on the IFN-c producing
cells and show differentiation phenotype of these HIV-1 specific cells as defined by CCR7 and CD45RA isoform. The terminally differentiated response
to the Pol peptide 356–374 (31.9% CCR72/CD45RA+ of gated cells) is diluted in the response to the entire Pol peptide pool (only 8.8% gated cells are
CCR72/CD45RA+).
doi:10.1371/journal.pone.0000321.g002
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responses of mature effector phenotype could only be found in
7/20 (35%) of the HIV-1 Progressors (p=0.015, Fisher’s exact
test)(Figure 3b).
In a subsequent analysis we determined the percentage of
terminally differentiated CD8+ T cell responses per individual. In
the HIV-1 Controllers a mean of 32% of all responses tested were
of the mature effector phenotype, while only a mean of 11% of
tested responses was terminally differentiated in HIV-1 progressors
(p=0.007, Mann Whitney test) (Figure 3c). For three HIV-1
Controllers, all tested epitopes demonstrated a mature effector
phenotype, a phenomenon that was not observed in any of the
HIV-1 progressors. However, the percentages of fully differenti-
ated HIV-1 specific T cell responses displayed a wide range (0%–
100% in HIV-1-Controllers and 0%–71% in HIV-1 progressors)
(Figure 3c).
Taken together, these data show that terminally differentiated
CD8+ T cell responses are more readily detectable in HIV-1
Controllers than in HIV-1 Progressors, demonstrating a qualitative
difference in CD8+ T cell differentiation between controlled and
progressive chronic HIV-1 infection.
Differentiation phenotype of a given epitope is
independent of HLA type and epitope specificity
Based on the large number of datapoints on the CD8+ T cell
phenotype of individual peptide-specific T cell responses described
above we evaluated potential predictive factors for the presence of
terminally differentiated responses, including the restricting HLA
class I allele and the specific targeted epitopes. We first
investigated if HIV-1 CD8+ T cell epitopes restricted by specific
HLA class I alleles were more likely to express CD45RA+/
CCR72 by testing a total of 45 optimal epitopes restricted by
HLA alleles frequently encountered in this study cohort (HLA-A2,
-A3, -B8, -B14, -B27 and -B57). As depicted in Figure 4a, there
was no clear association between the HIV-1-specific CD8+ T cell
effector phenotype and the restriction by specific HLA alleles. For
example, HLA-A2-restricted epitopes were terminally differenti-
ated in some individuals, but not in others, and different HLA-A-
restricted epitopes within one individual study subject displayed
different maturation phenotypes.
In addition, we investigated whether CD8+ T cells targeting
epitopes restricted by HLA-B27 and -B57, two alleles that have
Figure 3. Terminally differentiated HIV-1-speficic CD8+ T cells are more frequently detectable in HIV-1 Controllers compared to HIV-1
Progressors. (A) Percentage of CD45RA+/CCR72/CD8+ T cells for the 126 and 106 HIV-1-specific CD8+ T cell responses tested in HIV-1 Controllers
and Progressors, respectively. Frequencies of effector phenotype T cell responses were significantly higher in HIV-1 Controllers (squares) compared to
progressors (triangles). An HIV-1 specific CD8+ T cell response with .20% of CD45RA+/CCR72 cells was considered to be of terminally differentiated
phenotype (dotted line) [25]. (B) More HIV-1 Controllers had at least one terminally differentiated HIV-1 specific T cell response compared to HIV-1
Progressors (p=0.015, Fisher’s exact). (C) Of the CD8+ T cell responses against HIV-1 tested per individual a higher percentage of terminally
differentiated responses were detectable in HIV-1 Controllers (p=0.007, Mann Whitney). For 3 Controllers all investigated responses were of the
terminally differentiated phenotype, while five Controllers had none.
doi:10.1371/journal.pone.0000321.g003
Figure 4. Maturation phenotype of HIV-1 specific CD8+ T cells by HLA type and epitope specificity. Panel A shows the percentage of CD45RA+/
CCR72 CD8+ T cells of 46 HLA-A2, -A3, -B14, -B27 and -B57-restricted epitopes tested in the study cohort. Panel B depicts the percentage of
CD45RA+/CCR72 CD8+ T cells specific for six specific HIV-1 epitopes tested (restricting HLA allele and peptide sequence are shown). Data reflective
of a total of 21 study subjects, who had responses to the specific HLA-matched optimal epitopes tested (14 Controllers and 5 Progressors).
doi:10.1371/journal.pone.0000321.g004
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progressive HIV-1 infection, were predominantly of a terminally
differentiated phenotype [28–30] and found this not to be the case
(Fig 4b). For example, CD8+ T cell responses directed against the
HLA-B57-restricted epitope KAFSPEVIPMF, an epitope recog-
nized by the vast majority of HLA-B57 positive individuals, did
not show a mature effector phenotype in any of the study subjects.
In contrast, the HLA-B27-restricted epitope KRWIILGLNK, for
which there is strong evidence in the literature that viral escape
and loss of recognition of the epitope leads to disease progression
[28–30], had variable maturation phenotypes in different study
subjects despite the fact that all individuals tested for this epitope
were HIV-1 Controllers with comparable viral loads. Further-
more, CD8+ T cell responses directed against the same HIV-1
epitope exhibited variable maturation phenotypes in different
individuals irrespective of Controller or Progressor disease status
(Fig. 4b).
Taken together, these data suggest that maturation phenotype
of a given T cell response is not predictable by the restricting HLA
type or by the epitope specificity. This indicates that although full
maturation of CD8+ T cells clearly seems to occur more
frequently in HIV-1 Controllers, epitope-specific CD8+ T cells
can vary in their phenotype within a given individual, as do CD8+
T cell responses specific for the same epitope between different
individuals.
DISCUSSION
Recent studies indicate that the functional characteristics of virus-
specific T cells may be associated with the ability to control viral
replication [26,31]. We therefore performed a comprehensive
analysis of HIV-1 specific CD8+ T cell responses in untreated
HIV-1 infected individuals with progressive and non-progressive
disease. No differences between these two very distinct patient
populations were observed in terms of the magnitude and breadth
of HIV-1-specific CD8+ T cell responses as measured by antigen-
specific IFN-c production, consistent with previous reports [15–
17]. In contrast, terminally differentiated CD45RA
+/CCR7
2
HIV-1-specific CD8+ T cells were significantly more frequently
detectable in HIV-1 Controllers than in HIV-1 progressors, and
contributed an average of 32% to the total HIV-1-specific CD8+
T cell response in HIV-1-Controllers, compared to only 11% in
progressors. These data indicate that qualitative rather than
quantitative characteristics of HIV-1-specific CD8+ T cell
responses may be associated with differences in viral control and
HIV-1 disease outcome.
Based on the linear differentiation model of CD8+ T cells
defined by the lineage markers CD45RA and CCR7, it has been
proposed that chronic progressive HIV-1 infection is related to
a maturation block from effector memory phenotype (EM,
CD45RA
2/CCR7
2) to full effector phenotype (E, CD45RA
+/
CCR7
2)[20,27]. Our data in HIV-1 Controllers compared to
Progressors support this hypothesis, and are in line with recent
studies limited to a few epitopes by Hess et al. who used identical
differentiation markers demonstrating terminally differentiated
HIV-1 specific CD8+ T cells in 6 subjects with non-progressive
disease [25], and that early treatment of acute infection enhanced
the detection of such fully differentiated responses. Chen et al. [19]
compared EBV and HIV-1 specific CD8+ T cell responses in
a small number of subjects and demonstrated that HIV-1 specific
T cells in chronic HIV-1 infection lack CD45RA, also concordant
with the data presented in this study. The linear differentiation
model based on CD45RA and CCR7 as proposed by Champagne
et al. [20] and other groups is only one of the various models of
human T cell differentiation that have been proposed. However,
studies based on other differentiation markers such as CD27
revealed similar findings in that levels of HIV-1 specific T cells
exhibiting the CD8+/CD272 effector phenotype, which may
largely overlap with the CD45RA+/CCR72 phenotype of the
above quoted model, were associated with delayed disease
progression in untreated HIV-1 infection [32,33].
The present study represents an important extension beyond the
scope of previous studies of HIV-1 specific T cell maturation,
which were limited by small patient numbers and/or the
utilization of MHC class I tetramers for the identification of
HIV-1 specific T cells, which restrict the number, HLA types and
targeted epitopes that can be tested in a given individual. Most
reported studies have investigated at most 1–3 tetramers per
patient in populations that had to be selected for HLA class I
molecules and epitopes for which tetramers were readily available
(commonly HLA-A2 and HLA-B8)[19,25,33]. In most cases these
responses may only reflect a small fraction of the total HIV-1
specific response and selection for a narrow spectrum of HLA
types may add an additional bias to the interpretation of data on
a broader scale. Our simultaneous evaluation of multiple epitope-
specific responses representing the dominant virus-specific T cell
responses as determined by IFN-c revealed heretofore unappre-
ciated epitope-specific differences in CD8+ T cell differentiation,
comparing very distinct study populations at the extremes of viral
control. However, the use of peptides corresponding to HIV-1
clade B consensus sequences, and not to the autologous virus
sequence in the individual study subject may still have resulted in
the underestimation of the total virus-specific T cell response.
Not all epitopes in HIV-1 Controllers were of the effector
phenotype, and previously defined epitopes such as HLA-A2-
SLYNTVATL, which was investigated in all studies quoted above,
exhibited different effector phenotypes in different individuals
irrespective of controller or progressor status (Fig. 4). It is of
particular interest to note that T cell responses restricted by HLA
alleles associated with HIV-1 long-term nonprogression such as
HLA-B27orHLA-B57epitopesdidnotuniformlydisplayterminally
differentiated maturation status. In particular, in none of our study
subjects did we observe terminally differentiated CD8+ Tc e l l
response against the HLA-B57-restricted epitope KAFSPEVIPMF,
which the vast majority of individuals expressing HLA-B57
recognize. Interestingly, this epitope, unlike other HLA-B57-
restricted epitopes, is never found to exhibit sequence variation as
a consequence of viral escape in previous studies [34]. This finding
gives rise to the hypothesis that immature T cells lacking effector
phenotype are less likely to exert immune selection pressure on the
virus, a hypothesis that will need to be tested in future studies.
The observations outlined in this study raise the question as to
whether terminally differentiated HIV-1 specific effector cells
actually mediate viral control or if the setting of viral control
subsequently allows for full CD8+ T cell maturation. In some
studies addressing the functional properties of T cells such as
proliferation or direct cytotoxicity, no clear association with
effector phenotype defined by CCR7 and CD45RA could be
identified [26]. However, other studies have reported higher
granzyme and perforin content, elevated IFN-c production and
stronger direct cytolytic activity in CD8+ T cells with effector
phenotype. The exact association of maturation phenotype and
viral control may be much more complex and differentiated than
suggested by previous studies and future studies combining full
HIV-1 genome screening and the simultaneous use of a wide panel
of differentiation and functional markers facilitated by the advent
of high throughput multicolor flow-cytometry technology will aid
in dissecting the relationship between maturation status of CD8+
T cells and viral control.
CD8+ T Cell Maturation in HIV
PLoS ONE | www.plosone.org 6 March 2007 | Issue 3 | e321In conclusion, we show that fully differentiated CD8+ T cells
specific for HIV-1 are more frequently detectable in individuals
with exquisite control of HIV-1 infection and that impaired
effector cell maturation may contribute to chronic progressive
disease. Our data support the notion that the capacity for
complete differentiation of HIV-1 specific T cells is associated with
improved HIV-1 control and that phenotypic analysis is a useful
adjunct in the comprehensive assessment of virus-specific T cells.
However, differentiation phenotype is not predictable by HLA
type or epitope specificity, which indicates that the exact
association of maturation phenotype and viral control may be
much more complex and differentiated than previously appreci-
ated. Future studies combining full HIV-1 proteome CD4
+ and
CD8+ T cell screening and the simultaneous use of a wide panel of
differentiation and functional markers will aid in dissecting the
complexities of determining the exact properties of T cells needed
to confer viral control, which should facilitate the rational design
of new immunological and pharmaceutical approaches to viral
control.
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